期刊文献+

调强放疗与盐酸埃克替尼联合治疗晚期肺癌患者的疗效分析

下载PDF
导出
摘要 目的分析调强放疗与盐酸埃克替尼联合治疗晚期肺癌患者的临床疗效。方法选取我院收治的晚期肺癌患者66例,采取分层随机法分成两组,对照组(n=33)采取调强放疗,观察组(n=33)则在此基础上,加用盐酸埃克替尼,比较两组临床疗效。结果观察组患者近期总有效率(75.76%)高于对照组(57.58%),差异有统计学意义(P<0.05)。两组患者治疗前CEA、NSE、CA199水平比较,差异无统计学意义(P>0.05)。两组患者治疗后CEA、NSE、CA199水平低于治疗前,差异有统计学意义(P<0.05)。观察组患者治疗后CEA、NSE、CA199水平低于对照组,差异有统计学意义(P<0.05)。观察组不良反应率(24.24%)与对照组(18.18%)比较,差异无统计学意义(P>0.05)。结论调强放疗和盐酸埃克替尼联合效果显著,并且较为安全,是晚期肺癌的可靠治疗方案。
作者 佟彤
出处 《中国医药指南》 2019年第26期69-70,共2页 Guide of China Medicine
  • 相关文献

参考文献6

二级参考文献48

  • 1Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previouslytreated non-small-cell lung cancer (INTEREST): a randomised phase IIItrial. Lancet, 2008, 372(9652): 1809-1818.
  • 2Thatcher N,Chang A, Parikh P, et al Gefitinib plus best supportive care inpreviously treated patients with refractory advanced non-small-cell lungcancer: results from a randomised, placebo-controlled, multicentre study(Iressa Survival Evaluation in Lung Cancer). Lancet, 2005 , 366(9496):1527-1537.
  • 3Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications ofEGFR mutations in lung cancer. IntJ Clin Oncol, 2006,11(3): 190-198.
  • 4Sun Y, Shi Y, Zhang L, et al A randomized, double-blind phase III study oficotinib versus gefitinb in patients with advanced non-small cell lung cancer(nsclc) previously treated with chemotherapy (icogen). J Clin oncol, 2011,29(Suppl): abstr 7S22.
  • 5Shukuya T, Takahashi T, Kaira R, et al. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermalgrowth factor receptor mutations: a pooled analysis of published reports.Cancer Sci, 2011, 102(5): 1032-1037.
  • 6Hotta K, Ueoka H,Kiura K, et al. Safety and efficacy of gefitinib treatmentin elderly patients with non-small-cell lung cancer: Okayama Lung CancerStudy Group experience. Acta Oncol, 2005,44(7): 717-722.
  • 7Rossi D, Dennetta D, Ugolini M, et al. Activity and safety of erlotinib assecond- and third-line treatment in elderly patients with advanced non-smallcell lung cancer: a phase II trial. Targ Oncol, 2010,5(4): 231-235.
  • 8Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel inpulmonary adenocarcinoma. N EnglJ Med, 2009, 361(10): 947-957.
  • 9Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non-small cell lung cancer in the elderly: an analysis of the National CancerInstitute of Canada Clinical Trials Group Study Br.21. J Clin Oncol, 2008,26(14):2350-2357.
  • 10Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermalgrowth factor receptor underlying responsiveness of non-small-cell lungcancer to gefitinib. N EnglJ Med, 2004, 350(21): 2129-2139.

共引文献75

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部